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CD200 is a widely distributed membrane glycopro-
tein that regulates myeloid cell activity through its
interaction with an inhibitory receptor (CD200R).
The interaction is of interest as a target for treating
excessive inflammation and for treating leukemia.
There are closely related proteins to CD200R that
give activating signals making this a ‘‘paired recep-
tor.’’ We report X-ray crystallography structures
for the inhibitory CD200R, the activating receptor
CD200RLa, and a complex between CD200R and
CD200. Both CD200 and CD200R contain two Ig-
like domains and interact through their NH2 terminal
domains compatible with immunological synapse-
like interactions occurring between myeloid cells
and other CD200-expressing cells. The failure of the
activating receptor to bind CD200 resides in subtle
changes around the interface. CD200 has been
acquired by herpes viruses to mimic the host inter-
action. CD200R has evolved rapidly presumably
driven by pathogen pressure but it may also be
important in homeostasis through interactions with
commensal bacteria.
INTRODUCTION
CD200 (formerly termed OX2) is a widely distributed cell surface
protein that interacts with a receptor (CD200R) that is highly ex-
pressed onmyeloid and some lymphoid cells (Wright et al., 2000,
2003). CD200R contains tyrosine motifs that can be phospho-
rylated. These motifs signal through the recruitment of the
adaptor DOK2, which distinguishes CD200R from almost all
other inhibitory receptors, that contains immunoreceptor tyro-
sine-based inhibition (ITIM) motifs that provide inhibition
following recruitment of phosphatases (Mihrshahi et al., 2009;
Zhang et al., 2004). The broad tissue distribution of CD200 and
changes in its level of expression provide amechanism for locally
regulating myeloid cell activity at appropriate sites, such as
inflamed tissue (Barclay et al., 2002; Mukhopadhyay et al.,
2010; Nathan and Muller, 2001). The gene for CD200 has been
acquired by several viruses and in some cases has been shown
to cause downregulation of myeloid activity (Foster-Cuevas820 Structure 21, 820–832, May 7, 2013 ª2013 Elsevier Ltd All rightset al., 2004, 2011; Rosenblum et al., 2004; Zhang et al., 2009).
TheCD200/CD200R homeostaticmechanism is ofmajor interest
as a target for immunomodulation both to reduce myeloid activ-
ity in inflammatory conditions and to block inhibitory signals
provided by cancer cells. Inflammation is ameliorated by
cross-linking the receptor with CD200-Fc fusion proteins in
models of arthritis and allograft rejection (Gorczynski et al.,
1999, 2001) or by antibodies in virus-induced cytokine storm
(Snelgrove et al., 2008). High levels of CD200 have been associ-
ated with poor prognosis in certain cancers, suggesting that
CD200 may be protecting the tumor by inhibiting myeloid cells
through CD200R, and CD200 mAb are being tested to restore
myeloid cell activity and help eliminate tumor cells (Kretz-Rom-
mel et al., 2007; Moreaux et al., 2006; Tonks et al., 2007). The
CD200/CD200R interaction has similarities with the CD47 inter-
action with the SIRP paired receptor family in that both ligands
are widely distributed but receptors are restricted mainly to
myeloid cells and both CD200 and CD47 are targets for leukemia
therapy (Chao et al., 2012; Hatherley et al., 2008). However the
inhibitory SIRPa is a conventional inhibitory receptor using
ITIM motifs recruiting phosphatases (Barclay and Brown, 2006).
Both CD200 and CD200R contain two Ig-like domains and a
single-pass transmembrane region. They are heavily glycosy-
lated with six potential N-linked sites in CD200 and typically six
to ten in CD200R according to species (Barclay and Ward,
1982; Mallett et al., 1990; Wright et al., 2000, 2003). CD200R
is a member of a ‘‘paired receptor’’ family as in addition to
this inhibitory receptor there is one very closely related gene
with activating potential in humans and several in mice (Akkaya
and Barclay, 2010; Wright et al., 2003). These were termed
CD200RL for receptor-like but have also been termed
CD200R1, CD200R2, etc. (Gorczynski et al., 2004; Voehringer
et al., 2004). What is intriguing about several paired receptors
is that their extracellular regions typically have about 90% amino
acid sequence identity but there is a major difference in ligand
binding between the activating and inhibitory members. The
activating CD200RL proteins give negligible binding to CD200
so that the change of function from inhibitory to activatory is
associated with a loss of ability to interact with host ligand
(Hatherley et al., 2005). One theory is that this evolution is being
driven by pathogens targeting the inhibitory receptor (Akkaya
and Barclay, 2013; Barclay and Hatherley, 2008). The interaction
between CD200 and CD200R involves their NH2 terminal do-
mains and hence is predicted to span about four Ig-like domains
typical of interactions in immunological synapses (Figure 1).
Because CD200 is expressed on nonlymphoid cells as well asreserved
Figure 1. Schematic Illustrating Interactions between an Antigen-Presenting Cell and T Cell
Immunogloblin domains are shown as ovals. Fibronectin domains are shown as ovals with the letter F inside. Scavenger receptor cysteine-rich domains are
shown as rectangles. Tumor necrosis factor receptor (TNFR) and TNF domains are represented by long thin rectangles and long thin ovals, respectively. The
mucin-like structure of CD43 and the N-terminal glycosylated region of CD45 are shown as lines.
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CD200 Receptor Structuresleukocytes, it seems likely that synapse-like interactions may be
widely utilized (Wright et al., 2000).
We describe the X-ray crystallographic analysis of the extra-
cellular regions of the mouse CD200R, one of the activating
receptors, CD200RLa, and a complex between CD200R and
its ligand CD200.We discuss the implications for paired receptor
specificity, the evolution of these receptors and pathogen pres-
sure, and the implications of the topology of the interaction in
constraining the engagement of the receptor.
RESULTS AND DISCUSSION
Production of Recombinant Proteins for X-ray
Crystallographic Analysis
To provide homogenous protein for X-ray crystallography, the
extracellular regions consisting of two Ig-like domains of
CD200, CD200R, and CD200R-like proteins were expressed in
CHO cells that were defective in glycosylation so that the
N-linked glycosylation sites did not mature beyond the high
mannose state (Davis et al., 1993; Stanley, 1989), making it
possible to obtain more homogenous protein by endoglycosi-
dase H treatment. Glycoforms of CD200 and CD200R resistant
to endoglycosidase H were removed by passing the recombi-
nant proteins through a concanavalin A affinity column that pref-
erentially binds high mannose structures, allowing recombinant
protein deglycosylated back to N-acetyl-glucosamine (NAG) to
pass through the column (Figure S1 available online).
Crystallization and Structure Determination
Crystals were obtained for the extracellular regions of
CD200RLa, CD200R alone, and CD200R in complex with
CD200 and native diffraction data were recorded to 2.6, 2.1,Structure 21and 3.2 A˚, respectively (Table 1). The structure of CD200RLa
was solved after phase determination using crystals soaked in
gadolinium chloride solution because molecular replacement
(MR) phasing was unsuccessful. The structure of CD200R
was solved by molecular replacement using the coordinates of
CD200RLa as a search model (Figure 2). The coordinates of
CD200R were used as a MR search model for the CD200R/
CD200 complex and CD200 was built in a map calculated using
partial MR phases. Details of the crystallographic data collection
and refinement are given in Tables 1 and 2, and the structures
are given in Figures 2 and 3.
Structural Characteristics of CD200R and CD200RLa
CD200R and CD200RLa contain typical Ig-like domains consist-
ing of an NH2-terminal V-like domain followed by a smaller C2-
like domain. In both molecules, the A strand of the V-like domain
is on the extensive GFCC0C00 face as is commonly found in Ig-like
domains (Barclay, 2003) and there is a short alpha helix in the EF
loop of the V-like domain. NH2-terminal amino acid sequencing
confirmed the presence of an usually long NH2-terminal region
prior to the predicted beginning of the IgSF V-like domains of
CD200R and CD200RLa (Figure 4). The first NH2-terminal resi-
due for which electron density was observed is P15 in CD200R
and Q18 for CD200RLa. The absence of electron density for
the potentially glycosylated NH2-terminal region suggests this
region is flexible and able to adopt different conformations.
The structure of CD200RLa is very similar to that of CD200R,
as expected due to their high amino acid sequence identity in
their extracellular regions (86%). There are significant differ-
ences in the loops (BC, CC0, and DE) of the V-like domain, but
this is probably a consequence of their involvement in forming
crystal contacts in the CD200R crystal. Superposition of the, 820–832, May 7, 2013 ª2013 Elsevier Ltd All rights reserved 821
Table 1. Data Collection and Refinement Statistics
CD200RLa (native) CD200RLa (gadolinium) CD200R CD200/CD200R Complex
Data Collection Statistics
Beamline ID23-1 (ERSF) I03 (diamond) I04 (diamond) I04 (diamond)
Wavelength (A˚) 0.9762 1.7112 0.9795 0.9840
Resolution limits (A˚)a 168.02–2.5 (2.63-2.5) 137.05–3.5 (3.69-3.5) 38.84–2.08 (2.13-2.08) 86.04–3.22 (3.31-3.22)
Space group P6522 P6522 P41 21 2 P43 21 2
Unit cell dimensions (A˚, ) 157.76, 157.76,
167.91 90, 90, 120
158.25, 158.25,
167.5 90, 90, 120
51.97, 51.97, 175.42 128.17, 128.17, 115.08
90, 90, 90 90, 90, 90
Total number of
observations
151,989 93,847 116,395 101,278
Unique reflections 42,242 16,156 15,423 16,034
Multiplicitya 3.6 (3.5) 5.8 (5.9) 7.5(7.3) 6.3 (6.6)
Completeness (%)a 98.4 (99.7) 99.8 (99.8) 99.8 (99.5) 99.6 (99.5)
Is (I)a 13.0 (2.2) 10.9 (5.1) 16.8 (3.1) 10.2 (2.9)
Rmerge (%)
a,b 6.9 (49.4) 15.4 (39.0) 7.8 (73.8) 12.0 (68.3)
Ranom (%)
a,c 9.0 (15.9)
Processing programs MOSFLM/SCALA XIA2/SCALA XIA2 XIA2
Refinement Statistics
Resolution limits (A˚) 15.0–2.5 (2.56–2.5) 15.0–2.08 86.04–3.22
Number of reflections
in working set
39,601 14,424 14,465
Number of reflections
in test set
2,115 758 819
R-factor of working set a,d 0.171 (0.248) 0.198 (0.236) 0.199 (0.313)
Rfree
a,e 0.205 (0.291) 0.232 (0.270) 0.251 (0.360)
Number of atoms
(protein/carbohydrate/
water/otherf)
4,328/210/625/53 1,464/42/148/11 3,035/154/27/4
Residues in Ramachandran-
favored region (%)
98.4 97.3 94.1
Ramachandran outliers (%) 0.0 0.0 0.0
Rmsd bond lengths (A˚) 0.010 0.0100 0.007
Rmsd bond angles () 1.23 1.32 1.40
Average B factors (A˚2)
(protein/carbohydrate/
water/otherf)
45/83/55/107 39/42/48/55 93/122/63/68
aNumbers in parentheses refer to the appropriate outer shell.
bRmerge = 100 x (Shkl SijI(hkl;i)  < I(hkl) > j/Shkl SiI(hkl;i)), where I(hkl;i) is the intensity of an individual measurement of a reflection and < I(hkl) > is the
average intensity of that reflection.
cRanom = 100 x S jMn(I+) Mn(I)j/S (Mn(I+) + Mn(I)) where Ranom is the ratio between the mean intensity difference between Bijvoet pairs (jMn(I+) 
Mn(I)j) and the mean intensity of Bijvoet pairs (Mn(I+) + Mn(I).
dRfactor = (ShkljjFobsj  jFcalcjj/Shkl jFobsj), where jFobsj and jFcalcj are the observed and calculated structure facture amplitudes.
eRfree equals the R-factor of test set (5% of the data removed prior to refinement).
fOther atoms include polyethylene glycol, sulfate, glycerol, acetate.
Structure
CD200 Receptor StructuresV-like domains of CD200R and CD200RLa reflects these differ-
ences with an average root mean square deviation (rmsd) of
2.05 A˚ over 106 Ca atoms whereas the C2-like domains super-
impose with an rmsd of 0.6 A˚ over 80 Ca atoms.
Both CD200R and the CD200RLa contain disulfide bonds in
addition to the canonical disulfide of most Ig-like domains that
links beta strands B and F in each domain, which are largely
conserved in mammals. Intrasheet disulfides are found between
beta strand C0 and the C00D loop in the V-like domain and be-822 Structure 21, 820–832, May 7, 2013 ª2013 Elsevier Ltd All rightstween beta strands D and E in the C2-like domain. Interestingly,
the V-like domains of CD200R and CD200RLa have an exposed
Cys (C34) at the end of beta strand B to which a short portion of
continuous electron density was observed, and in which a Cys
(forming a disulfide bond with C34) was modeled (Figure S2).
This extra density was observed in the structures of CD200R
alone, CD200R in complex with CD200, and in all three indepen-
dent molecules of CD200RLa present in the asymmetric unit.
Because the crystallization conditions differ for each protein, itreserved
Figure 2. Structural Characteristics of
Mouse CD200R.
The mouse CD200R structure is shown as an
orange cartoon. Beta strands of each Ig-like
domain are labeled A-G. Observed N-acetylglu-
cosamine (NAG) moieties (N20, N69 and N168) are
shown as pink sticks and other potential N-linked
glycosylation sites are represented by pink
spheres N77, N135, N183 and N197. Disulfide
bonds are shown as yellow sticks. Cys 34 is shown
forming a disulfide bond with a free Cys (gray
stick). CD200R is rotated 180 in right hand panel.
See also Figure S2.
Table 2. Experimental Phasing Statistics for CD200RLa
Phasing Power SIR SAD
Resolution Bin Acentric Centric Acentric
78.8–11.08 A˚ 5.174 3.221 1.508
11.08–7.87 A˚ 3.400 2.192 1.172
7.87–6.44 A˚ 2.213 1.487 0.769
6.44–5.58 A˚ 1.457 0.990 0.505
Overall 0.918 1.064 0.359
FOM Acentrica FOM Centrica
78.8–11.08 A˚ 0.83238 0.71582
11.08–7.87 A˚ 0.71049 0.65144
7.87–6.44 A˚ 0.55196 0.54371
Overall 0.07967 0.15751
aThe overall figure of merit (FOM) is before density modification. After
solvent flattening, the FOM is 0.894. Only resolution bins with phasing
power >1 or FOM >0.5 are shown.
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CD200 Receptor Structuresis unlikely that the free Cys was modified by a component of the
crystallization solution. Presumably CD200R and CD200RLa
picked up Cys from the CHO cell medium during expression.
The roles of most of these extra disulfides are presumably
structural; however, other functional roles cannot be excluded
(Metcalfe et al., 2011).
Structural Characteristics of CD200
The structure of CD200was solved in complex with CD200R and
contains an NH2-terminal Ig V-like domain followed by a smaller
C2-like domain (Figure 3). The topology is very similar to that
of CD200R including the short alpha helix in the EF loop. The
CD200 C2-like domain is characterized by extremely high
B factors (130A˚2) despite packing against another CD200
molecule. In addition to a disulfide bond between beta strands
B and F in both IgSF domains of CD200, there is an exposed
disulfide bond between beta strands F and G in the V-like
domain. This disulfide bond is conserved in CD200 orthologs
(including viral ones discussed subsequently), but disulfides in
this position are unusual in Ig-like domains. NAG moieties were
modeled at all six of the N-linked glycosylation sites (N65, N73,
N80, N127, N151, and N160) of CD200.
Structure of the CD200/CD200R Complex
The structure of the CD200/CD200R complex shows near
orthogonal binding of the V-like domains of each molecule,
whereby the CD200 FCC0C00 face and CC0 and FG loops form a
concave surface that embraces the relatively flat AGFCC0C00
face and FG loop of CD200R (Figures 3A and 3B). Five NAG
moieties were modeled for the bound CD200R at the same
Asn as NAGs were modeled for CD200RLa. Despite the high
content of carbohydrate in both CD200 and CD200R, it is not
involved in the interaction, with N-linked glycosylation of both
CD200 and CD200R distant from the interface with the excep-
tion of N20 of CD200R, which lies at the periphery of the inter-Structure 21, 820–832, May 7, 2013action interface. The CD200/CD200R
interaction buries a total of 1768 A˚2 of
solvent-accessible area (901 A˚2 from
CD200 and 868 A˚2 from CD200R) and
shows high shape complementarity
with a shape correlation score (SC)
of 0.69. The interaction interface also
shows charge complementarity with
acidic patches on CD200R complement-ing basic patches on CD200 (Figures 3C and 3D) where a
network of polar interactions is clustered. Hydrogen bonds are
formed between residues (including water-mediated hydrogen
bonds) in the CD200R AGFCC0 beta strands (T17, E115, F114,
N113, E106, T47, T59), FG loop (P110, E111, N113) and the
CD200 FCC0 beta strands (T33, Q35, N44, T47, N94), and CC0
(S41, P42), C’’D (Q57) and the FG loops (T95, G97, S98, Q99,
K100). There are two salt bridges with K100 (FG loop) of
CD200-forming salt bridges with E106 (beta strand F) and
E115 (beta strand G) of CD200R. Hydrophobic interactions are
mediated between residues across the top of the FCC0C00 face
of CD200R and residues in the C strand and FG loop of
CD200. In particular F96 (in the FG loop) of CD200 mediates
numerous hydrophobic interactions where the phenyl ring sits
in a hydrophobic pocket formed by residues in the CD200R
CC0C00 beta sheet (L45, A61, Y62, K63, T68, N69, and E70).ª2013 Elsevier Ltd All rights reserved 823
Figure 3. Structure of the CD200/CD200R Complex
(A) The complex is shownwith CD200 in green andCD200R in orange. Beta strands of each Ig-like domain are labeled A–G. ObservedNAGmoieties are shown as
pink sticks and potential N-linked glycosylation sites are represented by pink spheres. Disulfide bonds are represented as yellow sticks.
(B) Representative electron density showing CD200 (green carbon atoms) and CD200R (orange carbon atoms) at the interaction interface. The final refinedmodel
is shown in 2Fo-Fc electron density (1 s) calculated at the end of refinement.
(C and D) Open book representation of the CD200 / CD200R interface. The surface of CD200R as viewed by CD200 (C). The molecular surface of CD200R is
shown colored by electrostatic potential with the residues at the interaction interface bordered by a black line. The surface of CD200 as viewed by CD200R (D).
The molecular surface of CD200 is shown, colored by electrostatic potential with the residues at the interaction interface bordered by a black line.
See also Figure S3.
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Figure 4. Sequence Alignment of the Extracellular Regions of the CD200R Family and CD200
The sequences for mouse CD200R (NP_067300), mouse CD200RLa (NP_997127) and human CD200R (NP_740750) are shown in (A) and the sequences for
mouse and humanCD200 (accession numbers NP_034948 and EAW79672 respectively) are shown in (B). Amino acid secondary structure is based on themouse
CD200R and CD200 structures. Residues identical between the sequences are highlighted in blue. NH2-terminal residues determined by protein sequencing are
highlighted in cyan; CD200RLa consisted of a mixture of two different NH2 termini differing by one amino acid starting with either Cys or Thr. The NH2 termini of
recombinant human and mouse CD200 was not detected presumably due to the presence of cyclized glutamine (pyroglutamic acid) as predicted from peptide
analysis of rat CD200 (Clark et al., 1985). Potential N-linked glycosylation sites are shown in pink. Cys residues forming disulfide bonds are numbered below the
alignment. Residues at the CD200/CD200R interface are denoted by asterisks. Cys residues forming disulfide bonds are numbered below the alignment.
Residues at the mouse CD200/CD200R interface are denoted by asterisks. Single point mutations of human CD200R (Hatherley and Barclay, 2004) and mouse
CD200 are highlighted according to their ability to bind human CD200 andmouse CD200R respectively; red denotes mutation results in < 25%wild-type binding,
yellow 25%–75%, and green > 75% binding.
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Figure 5. Single Point Mutations in CD200 at the CD200/CD200R
Interface Prevent CD200R Binding
(A) Surface plasmon resonance experiment shows immobilized CD200mutant
Q7K (green line) binds soluble CD200R similarly to wild-type (WT) CD200 (blue
line), whereas CD200 mutant N44A (red line) and the negative control CD4
(pink dashed line) do not bind CD200R. Injection of soluble CD200R over the
immobilized proteins is represented by the solid black bar.
(B) Single point mutation of CD200 at the crystallographic CD200/CD200R
interface prevents the interaction. The molecular surface of CD200 is shown in
Structure
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826 Structure 21, 820–832, May 7, 2013 ª2013 Elsevier Ltd All rightsSuperposition of the V-like domains (residues 17–126) of
CD200R alone and in complex with CD200 supports the earlier
suggestion that the NH2-terminal region of CD200R is flexible;
a rotation of the main chain around residue 17 results in residues
15-16 moving from the front GFC face (which would impede
binding to CD200) to the back BED face, exposing the CD200
binding face (Figure S3). Other than the NH2 terminus, there
are no significant changes to the interacting face of CD200R
upon binding. Conformational differences between the bound
and unbound CD200R are seen in the BC loop (residues 37–
41), DE loop (residues 82–87), and to a lesser extent in the EF
loop (residues 93–94). These loops are not involved in the
interaction with CD200, and these differences are due to the
different packing of the molecules within the crystals and also
reflect the plasticity of these loops.
Validation of the CD200/CD200R Interface
While some key residues in the CD200/CD200R interaction
had been identified in CD200R previously by mutagenesis there
were few data for CD200. Single point mutants of mouse CD200
containing a CD4 tag at the COOH terminus were expressed
in 293T cells and immobilized onto a BIAcore 3000 CM5 chip
precoated with a CD4 mAb. The ability of each CD200 mutant
to bind CD200R was assessed by passing over soluble
CD200R at 0.5 mM (the KD of the interaction at 25
C) and
comparing the binding responses with wild-type CD200. A
typical BIAcore experiment is shown in Figure 5A for wild-type
CD200, mutant CD200 proteins Q7K and N44A, and a negative
control protein CD4 (domains three and four). N44 of CD200 is
in beta strand C0, mediating hydrogen bonding with N113 of
CD200R, andmutation of N44 to alanine destroys this interaction
(Figure 5A). Residue 7 (Q7) of CD200 is not involved in the
interaction with CD200R and is located in beta strand A; hence
mutation of this residue to lysine (Q7K) did not affect binding to
CD200R. Mutation of other CD200 residues (L30, I31, L92,
N94, and F96) at the CD200R binding interface also effectively
destroyed ligand binding by disrupting either polar or hydropho-
bic interactions whereas mutations of residues outside the bind-
ing interface retained binding ability (Figure 5B; Table S1).
CD200 mutant Q27K gave 150% wild-type binding response.
Although Q27 does not make contact with CD200R, it is at the
periphery of the interface and mutation to lysine may allow salt
bridge formation with E70 of CD200R. All mutants were ex-
pressed well and reacted with the CD200 mAb OX90, which
recognizes a conformationally sensitive epitope (unpublished
observations).
The ligand binding domains of mouse and human CD200R
share 51% amino acid sequence identity (residues 1–123;the same orientation as in Figure 3D. Single point mutations of mouse CD200
are colored according to their ability to bindmouse CD200R. Residues colored
red denote mutation results in < 25% wild-type binding and green > 75%
binding.
(C) Mapping of single point mutations of human CD200R (Hatherley and
Barclay, 2004) onto the mouse CD200R structure delineates the CD200
binding site to the AGFCC0C00 face. Residues colored red denotes mutation
resulting in < 25% wild-type binding, yellow 25%–75% and green > 75%
binding. (B) and (C) are in the same orientation as Figures 3D and 3C,
respectively.
See also Table S1.
reserved
Figure 6. The Inability of CD200RLa to Bind
CD200
(A) The structure of CD200 (green cartoon) in
complex with CD200R (orange surface) is shown.
Residues differing between CD200La and
CD200R are colored cyan. Additional residues of
CD200RLa that differ from the CD200R sequence
crystallized but that are found in other CD200R
variants (from Ensembl database, http://www.
ensembl.org) are colored white. Three residues
of CD200R that differ from CD200RLa that are at
or peripheral to the CD200/CD200R interface are
labeled.
(B) Left panel: transparent surface and cartoon
representation of the CD200 (green) in complex
with CD200R (orange); F36 and F114 are shown as
sticks and colored purple. Right panel: virtual
complex between CD200RLa (cyan) and CD200
(green); F36 and L114 are colored purple and the
loss of the N-terminal strand from the interface is
highlighted.
(C) Surface plasmon resonance experiments show
that mutation of three CD200RLa residues (N63,
K66 and L114F) is required to gain CD200 binding
(60% of wild-type). Recombinant CD200R, wild-
type CD200RLa, and mutant CD200RLa were
immobilized on a BIAcore chip and increasing
concentrations of CD200 were injected over the
proteins. A representative experiment is shown.
KDs were calculated by nonlinear curve fitting. The
number (n) of times the experiment was repeated
and the standard deviation (SD) of the KDs calcu-
lated are given.
For differences between the receptors, see align-
ment in Figure S4.
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similar affinity as mouse CD200 (KDs of 7 and 4 mM at 37
C,
respectively) (Foster-Cuevas et al., 2004; Hatherley et al.,
2005). Hence the interaction is likely to be similar for both spe-
cies allowing data from a previous mutagenesis study of the
human proteins (Hatherley and Barclay, 2004) to be mapped
onto the mouse CD200/CD200R complex. All mutated residues
in human CD200R that gave less than 25% binding to CD200 as
compared to wild-type protein are located at the mouse CD200/
CD200R interaction interface (Figure 5C) and mutations that had
an intermediate effect (25%–75%) are at the periphery of the
interaction interface.
Why Doesn’t Mouse CD200RLa Bind CD200?
Despite CD200RLa sharing a high amino acid sequence identity
with CD200R in the V-like domain (84% identity in residues 1–
123), it gives minimal binding to CD200 (50-fold lower affinity;
Wright et al., 2003). Comparison of the CD200R and CD200RLa
sequences does not show simple changes in the contact resi-Structure 21, 820–832, May 7, 2013dues that might explain why the acti-
vating receptor CD200RLa does not
bind CD200, implying indirect effects.
To investigate this, the structure of the
V-like domain of CD200RLa was super-
imposed onto CD200R in complex withCD200. CD200RLa and CD200R differ by 20 amino acids in
the V-like domain but genome analysis shows that three of these
are found as natural variants in CD200R, indicating 17 definitive
differences. The first four differences between the twomolecules
are in the NH2-terminal region (residues 1–15), which is not seen
in the structure of CD200RLa. Many of the amino acid differ-
ences are distant or peripheral (residues 23, 28, 29, 38, 41, 42,
52, 54, and 117) to the interface (Figure 6A). Residues 63 and
66 in the C0C00 loop differ between CD200R and CD200RLa
and are at the periphery of the interaction with K63, making con-
tact with F96 and L30 of CD200. Although residue 66 is not
directly involved in the interaction, a difference at this position
may adversely affect positioning of residue 63. Single point mu-
tation of either residues 63 or 66 of CD200RLa to the equivalent
residue in CD200R (N63K and K66T, respectively) does not result
in CD200 binding. However the CD200RLa double mutant N63K
K66T does bind CD200, although with an affinity (KD = 18.4 mM)
about 30 times weaker than that with CD200R (Figure 6B).
Residue 114 in beta strand G is Phe in CD200R and makesª2013 Elsevier Ltd All rights reserved 827
Figure 7. Topology of the CD200/CD200R Interaction at the Cell Surface
The dimensions of the CD200/CD200R interaction are compared to other interactions thought to occur in immunologic synapses. A model of the CD47/SIRPa
interaction was generated by superimposing the crystal structure of the full extracellular domain of SIRPa (Protein Data Bank ID [PDB] code 2wng) onto the crystal
structure of the V-like domain of SIRPa in complexwith CD47 (PDB code 2jjs). Cartoons for the crystal structures of PD-1/PD-L1 (PBD code 3bik), CD4/TCR/MHC
(PDB code 3t0e), and CTLA-4/CD80 (PDB code 1i8l) are shown. The approximate dimensions of the interacting protein complexes are shown. The last observed
COOH-terminal residue in each structure is represented as a sphere. The number of amino acid (aa) residues that link the protein structures to their predicted
transmembrane regions are given. Observed NAG and mannose moieties are shown as pink sticks and the sites of potential N-linked glycosylation sites are
shown as pink spheres.
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CD200 Receptor Structurescontact with N44 of CD200. However, it also stacks against F36
in CD200R and together these stacked aromatic residues are
involved in hydrophobic interactions with the NH2-terminal
strand of CD200R, helping to stabilize the CD200 binding confor-
mation of residues 15–20 of CD200R (Figure 6B). Substitution
of F114 for Leu in CD200RLa seems to cause the side chain of
F36 to flip in the opposite direction into the core of the domain.
This in turn leads to the destabilization of the NH2 region of
CD200RLa and therefore disruption of the CD200 binding inter-
face (Figure 6B). Mutation of L114 of CD200RLa to Phe (L114F)
results in binding to CD200 with a KD of 4.2 mM, about seven
times weaker than the CD200/CD200R interaction (Figure 6C).
Thus both regions are important in explainingwhy theCD200RLa
does not bind CD200 and this argument was strengthened
by the analysis of a CD200RLa triple mutant combining both
regions (N63K, K66T, and L114F) that binds CD200 with a similar
affinity as CD200R (Figure 6C).
The three residues that are critical for CD200RLa not binding
CD200 are not conserved in the other activating receptors, indi-
cating that these fail to bind CD200 for different reasons (Fig-
ure S4). This resembles the situation seen in the SIRP family,
where two activating alleles of SIRPb use different mechanisms
not to bind ligand (Hatherley et al., 2008). In addition, the
CD200RLb differs greatly from the other activating receptors
with only 32% amino acid identity with CD200R in the V-like
domain (residues 1–124) and many residues could be important
in its failure to bind CD200.
Topology of the CD200/CD200R Interaction
The structure of the CD200/CD200R complex allows the
topology of the interaction between two opposing cells to be
modeled. The distance between the last residues of each mole-
cule in the structural model is 12 nm; this appears somewhat
smaller than the 14 nm typically found for protein interactions
spanning the immunological synapse; however, a further nine828 Structure 21, 820–832, May 7, 2013 ª2013 Elsevier Ltd All rightsresidues of CD200R need to be accounted for before entering
the predicted transmembrane region. Allowing for these linking
residues suggests that the distance spanned between two
opposing cells is likely to be similar to other well-characterized
interactions involved in fine tuning of the immune response
such as those found in the T cell immunologic synapse (Figure 7).
As this interaction occurs between mostly myeloid cells and a
variety of other cell types including epithelial cells, the topology
indicated supports a previous proposal (Wright et al., 2000)
that synapse-like interactions may be found in a variety of cell
types and more specifically to regulate myeloid cell function
(such as CD200/CD200R and CD47/SIRPa; Figure 7).
There are many functional data indicating that the CD200/
CD200R interaction acts between cells (trans) (Foster-Cuevas
et al., 2004; Kretz-Rommel et al., 2007). The possibility that it
occurs also in cis seems unlikely given the steric constraints
from the extensive glycosylation of both proteins, in particular
at residues Asn127 and Asn151 of CD200. In addition CD200
is widely expressed compared to CD200R and rarely on the
same cells so this is unlikely to be amajor factor (Mukhopadhyay
et al., 2010; Wright et al., 2001).
Implications of Paired Receptor Function and Evolution
The CD200/CD200R Interaction and Viral Orthologs
When the sequences of CD200 and CD200R are compared
across species, it is clear that CD200R is evolving more rapidly
that CD200 (Figure 8). Viruses are constantly evolving to subvert
the immune system and CD200-like orthologs containing two
Ig-like domains have been identified in beta- and gammaherpes-
viridae (Foster-Cuevas et al., 2004). The human herpesvirus-8
(HHV-8; Kaposi sarcoma virus) CD200 ortholog (K14) mimics
the interaction of human CD200 with CD200R to suppress
macrophage and T cell responses to virus and K14 binds
CD200R with the same affinity as the host CD200 protein
(Foster-Cuevas et al., 2004; Misstear et al., 2012). The ratreserved
Figure 8. The CD200/CD200R Binding Site
Is Conserved in Mammals and Some Vi-
ruses
The ConSurf Server (Ashkenazy et al., 2010) was
used to estimate the evolutionary conservation of
amino acids in CD200 and CD200R using a mul-
tiple sequence alignment of mammalian (and two
viral) CD200 and CD200R orthologs (generated by
Clustal W2 (Larkin et al., 2007) and the CD200/
CD200R coordinates.
(A) Left panel: conservation of CD200R amino
acids in the following mammals: mouse
(NP_067300.1), human (NP_620161.1), chimp
(XP_001156654.1), monkey (XP_001105494.1),
wolf (XP_545099.2), cow (XP_002684796.2), and
rat (NP_076443.1). The view of CD200R is the
same as that in Figure 3C. Centere panel: con-
servation of CD200 amino acids in the following
mammals: mouse (NP_034948.3), human
(NP_001004196.2), chimp (XP_516648.3), monkey
(XP_001104031.1), wolf (XP_849283.2), cow
(NP_001029792.1), and rat (NP_113706.1). The
view of CD200 is the same as that in Figure 3D.
Right panel: conservation of CD200 amino acids in
mammals (as in center panel) and the viral ortho-
logs K14 (AAK53415.1) and e127 (AAO45420.1)
from the human herpes virus 8 (HHV8) and the rat cytomegalovirus (RCMV), respectively. The black line outlines the residues at the CD200/CD200R interface.
The relative degrees of residue conservation are colored from blue for variable positions to dark pink for conserved residues.
(B) CD200R and CD200 are rotated 180 from (A).
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CD200 Receptor Structurescytomegalovirus (RCMV) CD200 ortholog e127 also mimics the
host protein in terms of affinity (Foster-Cuevas et al., 2011).
Most of the residues in K14 and e127 predicted to be at the
CD200R interface are mostly either identical or conservative
changes compared to human and rat CD200, respectively,
although the overall amino acid sequence identity in the V-like
domain is 41% and 87%, respectively (Foster-Cuevas et al.,
2004). This is illustrated in Figure 8, which compares the
CD200s frommammals and includes the viral orthologs; it shows
there is considerable divergence in domain 2 but less in the bind-
ing face in domain 1. It has been suggested that the heterogene-
ity in the paired receptors is a result of pathogen pressure where
pathogens target the inhibitory receptors. These then evolve
both by sequence change and by the generation of activating
genes that no longer bind the host ligand but may provide de-
coys for pathogens targeting the inhibitory receptor (the counter-
balance theory; Barclay and Hatherley, 2008). With regard to
CD200/CD200R, the viral orthologs of CD200 may not be the
driving force for the evolution of these activating receptors
because they mimic the host CD200 so closely as indicated by
their similar affinities. Thus the evolution of the CD200R family
may have been driven by as yet unidentified pathogens.
Conclusions
The structures indicate that CD200 and CD200R consist of two
typical Ig-like domains interacting though their NH2-terminal
domains so that the interaction has dimensions compatible
with functioning in an immunological synapse. What is unusual
about this interaction is that CD200 is expressed widely on
endothelial and epithelial cells, suggesting that immunological
style synapses may be important in these types of interactions
in addition to the well-characterized interactions between
leukocytes. Restricting the interaction to synapse-like regionsStructure 21may limit the conditions in which the receptor gets phosphory-
lated and may restrict access to pathogens targeting this recep-
tor as suggested for the CD47/SIRPa interaction (Barclay and
Hatherley, 2008; Hatherley et al., 2008). This interaction has
many similarities to the CD200/CD200R interaction whereby a
widely distributed ligand (CD47) reacts with a receptor restricted
to myeloid cells (SIRPa) and the interaction is also a target for
enhancing immunity to cancer (Chao et al., 2012).
One feature of CD200R is its extensive glycosylation (eight to
ten N-linked sites depending on species) and that this glycosyl-
ation is distant from the interacting faces (Figure 3A). It is
possible that this prevents unwanted interactions that might
occur during the rapid evolution of the receptor and indeed
this may be a common role for glycosylation of many leukocyte
receptors that are generally evolving fast compared to those of
other cell types (Barclay, 2003).
The finding that subtle changes around the binding site are
responsible for the failure of the activating receptors to bind
CD200 is reminiscent of other paired receptors such as theSIRPs
(Hatherley et al., 2008). This suggested that the activating recep-
tor has evolved from the inhibitory receptor and specifically to
not bind host ligand. In this way it provides a defensemechanism
for pathogens that are targeting the inhibitory receptors (dis-
cussed in Barclay and Hatherley, 2008). The finding that many
virus types have acquired CD200 orthologs supports this
concept. In some viruses (e.g., HHV8 and rCMV), the CD200
ortholog acts as a closemimic in termsof binding. Thus the struc-
tures provide evidence for a paired receptor system involved in
homeostasis that is evolving rapidly under pathogen pressure.
Given the importance of myeloid cells and their expression of
CD200R, it seems likely that interactions with the microbiome
may well be reflected in setting the levels of immune responses
(Akkaya and Barclay, 2013). The presence of polymorphisms, 820–832, May 7, 2013 ª2013 Elsevier Ltd All rights reserved 829
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CD200 Receptor Structuresand heterogeneity in the repertoire of the CD200 paired receptor
system may be important in disease susceptibility.
EXPERIMENTAL PROCEDURES
Expression and Production of Recombinant Proteins for
Crystallization
Recombinant mouse CD200RLa comprising the leader sequence, the two
extracellular IgSF domains (residues 1–237, accession number NP_997127)
followedby aC-terminal polyhistidine tag (STRHHHHHH)was expressed using
the pEE14 vector in the CHO Lec3.2.8.1 cell line. The extracellular regions of
mouse CD200R (residues 1–232; accession number NP_067300) and mouse
CD200 (residues 1–232; accession number NP_034948) were also expressed
with a C-terminal polyhistidine tag in the same manner as mouse CD200RLa.
The recombinant proteins were purified by nickel affinity chromatography
and buffer exchanged into 10 mM HEPES pH 7.5, 150 mM NaCl, 0.02%
NaN3 (HBS). N-linked sugars were removed using 2.5 U of Endoglycosidase
Hf (NEB) per microgram of protein. Recombinant CD200R and CD200 were
further purified by passing through a concanavalin A (Con A) Sepharose 4B
column (GE Lifesciences), collecting the protein in the flow-through. Recombi-
nant CD200 andCD200R eluted from the concanavalin A columnwere used as
ligands inmutagenesis experiments (see subsequent section). All recombinant
proteins were gel-filtrated into HBS buffer to remove contaminants and
aggregated protein.
NH2-terminal protein sequences were determined using an automated
Edman degradation in an Applied Biosystems Procise 494A protein sequencer
(Perkin-Elmer Ltd, UK).
Crystallization
Sitting drop vapor diffusion crystallization experiments were performed using
an OryxNano robot (Douglas Instruments) to dispense nanoscale protein-pre-
cipitant drops that were equilibrated against precipitant reservoirs at either
12C or 20C. CD200RLa was concentrated to 9.6 mg/ml and P6522 crystals
grew (within 24 hr) from 300 nl drops containing 50% and 66% protein from
0.2M sodium chloride, 0.1M sodium cacodylate pH 6.5, and 2.0M ammonium
sulfate at 12C. Crystals were cryoprotected in mother liquor supplemented
with 20% glycerol and flash frozen in liquid nitrogen.
P41212 crystals of CD200R grew from drops containing a 1:1 molar mix of
CD200 and CD200R (each protein at 320 mM). Crystals grew (within 2 weeks)
from 400 nl drops containing 50% and 70% protein from 0.2 M ammonium
acetate, 0.1 M sodium acetate pH 4.0, 15% w/v PEG 4000 at 20C. The
CD200R crystal was cryoprotected in mother liquor supplemented with 20%
glycerol and flash frozen in liquid nitrogen.
For the CD200/CD200R complex (each protein at 350 mM), crystals grew at
20C from a 400 nl drop containing 70% protein from 1.0 M imidazole pH 7.0
and were cryoprotected in mother liquor containing 35% ethylene glycol and
flash frozen in liquid nitrogen.
Data Processing and Structure Determination
A native X-ray diffraction data set for mouse CD200RLa was collected at the
European Synchrotron Radiation Facility (ESRF, Grenoble) at a wavelength
of 0.9762 A˚ and was processed using Mosflm (Leslie, 1992) and SCALA
(Evans, 1997). To obtain heavy metal derivatives, CD200RLa crystals were
soaked in 65 mM gadolinium chloride for 2 minutes, cryoprotected in mother
liquor containing 20%glycerol, and flash frozen in liquid nitrogen. A gadolinium
derivative diffraction data set was collected at the Diamond Light Source (UK)
at 1.7112 A˚ (the LIII absorption edge). Derivative data were processed using
the Xia2 data processing suite (Winter, 2010). The autoSHARP suite of pro-
grams (Fortelle and Bricogne, 1997) was used to generate initial phases in a
single isomorphous replacement with anomalous signal (SIRAS) experiment
using the native and derivative data sets. SHELX D found six gadolinium sites
and SHARP refined the coordinates, occupancy, and B factors for these sites
and generated residual maps and phases. Solvent flattening was performed
by SOLOMON to give new phases to 2.5 A˚ into which 561 residues of
mCD200RLa were autobuilt by the Buccaneer program (Cowtan, 2006). Itera-
tive cycles of manual model building in COOT (Emsley and Cowtan, 2004) and
refinement with BUSTER-TNT (Blanc et al., 2004) were performed.830 Structure 21, 820–832, May 7, 2013 ª2013 Elsevier Ltd All rightsDiffraction data for CD200R and the CD200/CD200R complex were
collected at Diamond on beamline I04 at 100 K (Table S1). Diffraction data
sets were processed using Xia2 (Winter, 2010). The structure of CD200R
was determined by molecular replacement using Phaser (McCoy et al.,
2007) with the CD200RLa structure as a search model. Domains 1 and 2 of
CD200RLa were initially used sequentially as molecular replacement search
models by Phaser to determine initial phases for CD200R. Buccaneer was
used to autobuild followed by iterative cycles of refinement with autoBUSTER
(Bricogne et al., 2011) and manual model building in COOT.
The structure of the CD200/CD200R complex was initially solved by molec-
ular replacement using Phaser with domains 1 and 2 of CD200R. Phases
calculated from this partial model using autoBUSTER produced a map with
clear density that allowed placement of a canonical immunoglobulin domain
(domain 1 from 3ALP). Refinement of this model allowed manual placement
of the second domain. Iterative cycles of refinement with autoBUSTER (Bri-
cogne et al., 2011) and manual model building in COOT produced a complete
model for CD200, with the positions of the glycosylated Asn residues verifying
the remodeled sequence. Molecular graphics were generated using Pymol
(http://www.pymol.org; Schro¨dinger). Electrostatic surface potentials were
calculated using the Pymol APBS Tools 2 plugin. The CD200/CD200R struc-
ture was analyzed using the protein interfaces, surfaces, and assemblies ser-
vice PISA at European Bioinformatics Institute (http://www.ebi.ac.uk/pdbe/
prot_int/pistart.html) (Krissinel and Henrick, 2007).
CD200 Mutagenesis and Analysis by Surface Plasmon Resonance
Surface plasmon resonance experiments were performed using a BIAcore
3000 at 25C. Recombinant CD200R and CD200 eluted from respective Con
A columns (see expression section above) were gel-filtrated in HBS. The extra-
cellular region of CD200 (residues 1–232) was tagged at the C terminus with
domains 3 and 4 of rat CD4 (CD4) followed by a biotinylation (Bio) site and tran-
siently expressed by 293T cells as described previously (Brown et al., 1998).
Single point mutants of CD200 were generated by overlap extension polymer-
ase chain reaction. OX68 mAb (mouse anti-rat CD4) was amine coupled to a
CM5 chip and approximately 650 response units (RUs) of each protein immo-
bilized. Serial dilutions of CD200R were injected over immobilized wild-type
and mutant CD200 and CD4 control protein. A kD of 0.5 mM was calculated
from equilibrium binding data and this concentration of CD200R was used
to test the binding ability ofmutant CD200 proteins compared towild-type pro-
tein. A CD200 mAb (OX90) was passed over the proteins at 0.2 mg/ml. The
ligand and antibody responses obtained for the control CD4 protein were sub-
tracted from the wild-type and mutant CD200 responses to obtain the specific
binding response for each protein. To compensate for any variation in protein
levels immobilized on each flow cell the specific binding response for each
protein was divided by the amount of protein immobilized and then expressed
as a percentage of wild-type protein (100%). The OX68 chip was regenerated
by passing over 0.1 M glycine HCl pH 2.0 to remove immobilized proteins.
Similarly, CD200R (residues 1–232) and wild-type and mutant CD200RLa
(residues 1–237) CD4-Bio chimeric proteins were expressed and immobilized
via OX68 onto a CM5 BIAcore chip. Increasing concentrations of CD200 were
injected over the immobilized proteins and KDs were obtained by nonlinear
curve fitting to the data.
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